[Circulating proteinic biomarkers and breast cancer]
- PMID: 16876456
- DOI: 10.1016/j.gyobfe.2006.06.011
[Circulating proteinic biomarkers and breast cancer]
Abstract
Circulating proteinic biomarkers are secreted by tumor cells or by their environmental cells and they have a variable specificity. In case of breast cancer, carcino-embryonic antigen (CEA) was for a long time the only circulating biomarker used. Nowadays, the most useful biomarkers measure circulating levels of fragments of MUC1-polymorphic epithelial mucin (MUC1-PEM): cancer antigen (CA) 15.3, mucin-like carcinoma-associated antigen (MCA), CA 27-29, CA 549... They are useful for general disease follow-up. Other circulating markers belonging to keratins (tissue polypeptide antigen, TPA, TPS or Cyfra 21.1) are correlated with proliferative activity of breast tumors. More recently, the measure of the c-erb B2 circulating part (extra cellular domain, ECD) was proposed as a prognostic biomarker for breast tumors with c-erb B2 overexpression. Moreover, the determination of urinary level of trefoil factor1 (PS2-TFF1) might be useful for the follow-up of hormonodependent breast cancers. The present review describes the clinical interest of these different circulating biomarkers in case of breast cancer, emphasizing their biological characteristics.
Similar articles
-
Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).Clin Chem Lab Med. 2002 Mar;40(3):298-303. doi: 10.1515/CCLM.2002.047. Clin Chem Lab Med. 2002. PMID: 12005221
-
Mucin-like cancer-associated antigen (MCA) compared with CA 15-3 in advanced breast cancer.Klin Wochenschr. 1989 Aug 17;67(16):813-7. doi: 10.1007/BF01725197. Klin Wochenschr. 1989. PMID: 2796251
-
Tumor markers in the early detection of tumor recurrence in breast cancer patients: CA 125, CYFRA 21-1, HER2 shed antigen, LDH and CRP in combination with CEA and CA 15-3.Clin Chim Acta. 2016 Oct 1;461:1-7. doi: 10.1016/j.cca.2016.07.014. Epub 2016 Jul 22. Clin Chim Acta. 2016. PMID: 27451906
-
Circulating tumour markers in breast cancer.Eur J Nucl Med Mol Imaging. 2004 Jun;31 Suppl 1:S15-22. doi: 10.1007/s00259-004-1523-z. Epub 2004 May 4. Eur J Nucl Med Mol Imaging. 2004. PMID: 15127239 Review.
-
Blood-based biomarkers in breast cancer: From proteins to circulating tumor cells to circulating tumor DNA.Tumour Biol. 2018 May;40(5):1010428318776169. doi: 10.1177/1010428318776169. Tumour Biol. 2018. PMID: 29775157 Review.
Cited by
-
Mass spectrometry (LC-MS/MS) identified proteomic biosignatures of breast cancer in proximal fluid.J Proteome Res. 2012 Oct 5;11(10):5034-45. doi: 10.1021/pr300606e. Epub 2012 Sep 20. J Proteome Res. 2012. PMID: 22934887 Free PMC article.
-
Translational progress on tumor biomarkers.Thorac Cancer. 2015 Nov;6(6):665-71. doi: 10.1111/1759-7714.12294. Epub 2015 Jul 27. Thorac Cancer. 2015. PMID: 26557902 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous